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Abstract
Hypoxia inducible factor-1 (HIF-1) is a transcriptional factor responsible for cellular and tissue
adaption to low oxygen tension. HIF-1, a heterodimer consisting of a constitutively expressed β
subunit and an oxygen-regulated α subunit, regulates a series of genes that participate in
angiogenesis, iron metabolism, glucose metabolism, and cell proliferation/survival. The activity of
HIF-1 is controlled by post-translational modifications on different amino acid residues of its
subunits, mainly the alpha subunit. Besides in ischemic stroke (see review [1]), emerging evidence
has revealed that HIF-1 activity and expression of its down-stream genes, such as vascular
endothelial growth factor and erythropoietin, are altered in a range of neurodegenerative diseases.
At the same time, experimental and clinical evidence has demonstrated that regulating HIF-1
might ameliorate the cellular and tissue damage in the neurodegenerative diseases. These new
findings suggest HIF-1 as a potential medicinal target for the neurodegenerative diseases. This
review focuses on HIF-1α protein modifications and HIF-1’s potential neuroprotective roles in
Alzheimer’s (AD), Parkinson’s (PD), Huntington’s diseases (HD), and amyotrophic lateral
sclerosis (ALS).
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1. Introduction
The oxygen tension-dependent transcriptional factor, hypoxia inducible factor-1 (HIF-1), is
responsible for the induction of genes that facilitate the adaption and survival of cells
exposed to hypoxia [2]. HIF-1 activation induces a diverse range of target genes,
encompassing a wide variety of cellular processes, including angiogenesis, erythropoiesis,
energy metabolism, cell proliferation, and cell cycle control [3]. HIF-1 can improve the
redox environment [4], increase blood oxygen and glucose supply, and affect iron
metabolism by regulating its target genes.
The brain consumes a large quantity of oxygen and demonstrates a high vulnerability at
conditions with impaired oxygen supply. It has been suggested that reduced oxygen supply
plays a key role in neurodegeneration during the aging process [5]. Pathological processes
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such as oxidative stress, impaired oxygen or glucose supply, and disruption of iron
homeostasis are common in neurodegenerative diseases [6–8]. This raises the possibility that
HIF-1 is a potential therapeutic target for these neurodegenerative diseases. In this review,
we focus on the mechanisms of HIF-1 regulation and roles of HIF-1 in neurodegenerative
diseases including amyotrophic lateral sclerosis (ALS), Alzheimer’s (AD), Parkinson’s
(PD), and Huntington’s diseases (HD). We also summarized recent drug development based
on HIF-1 pathway in neurodegenerative diseases.
2. HIF-1 modifications, expression, and activation
HIF-1 is a heterodimetric complex consisting of a constitutively expressed β subunit (also
known as the aryl hydrocarbon receptor nuclear translocation, ARNT) and a hypoxia
inducible subunit, α subunit [2]. Both subunits belong to the basic helix-loop-helix (bHLH)-
PER-ARNT-SIM (PAS) protein family. The bHLH and PAS motifs are required for
dimerization between HIF-1α and HIF-1β. HIF-1α possesses a unique oxygen-dependent
degradation domain (ODDD), which mediates oxygen-regulated stability, and two
transactivation domains, N-terminal (N-TAD) and C-terminal (C-TAD) [9–10]. Under
hypoxia, HIF-1α is stabilized and translocated to the nucleus where it dimerizes with HIF-1β
[3]. The activated HIF-1 complex subsequently binds to hypoxic response elements (HREs)
in the regulatory regions of genes and recruits co-transactivation factors such as CBP/p300
[CBP: CREB (cAMP-response element-binding protein)-binding protein/E1A-binding
protein]. It induces transcription of more than a hundred genes with various functions. The
activity of HIF-1 is mainly controlled through regulating the protein level of HIF-1α [3].
Although the transcription and the synthesis of HIF-1α are constitutive, its protein
degradation and transcriptional activity are regulated by post-translational modifications on
different amino acid residues in different domains as discussed in the following and
summarized in Scheme 1 and Table 1.
1. HIF-1α protein can be hydroxylated. Prolyl hydroxylation determines HIF-1α
degradation in normoxia. HIF-1α is hydroxylated on the prolyl residues 402 and
564 within the ODDD [11]. Both sites of modification contain a conserved
LXXLAP motif and the hydroxylation is taken place at their 4-positions [11]. The
hydroxylation is mediated by a family of prolyl hydroxylases, namely PHD1,
PHD2, and PHD3 [12], among which PHD2 has the highest specificity for
hydroxylation of HIF-1α [11]. These PHD enzymes are 2-oxoglutarate-dependent
dioxygenases and require oxygen as well as Fe2+ as cofactors [13–14].
Hydroxylation promotes interaction of HIF-1α with the von Hippel-Lindau (pVHL)
ubiquitin E3 ligase complex [15–16]. HIF-1α is thereby poly-ubiquitinated and
degraded by the 26S proteasome [17–18]. Since the PHDs employ non-heme iron
in the catalytic moiety, it can be predicted that shortage of intracellular iron will
result in inhibition of activity of PHDs and HIF-1 upregulation. As the result, iron
chelators have been used to upregulate HIF-1α expression [19].
2. At the transcriptional level, oxygen availability enables hydroxylation of the
asparagine residue 803 in the C-TAD of HIF-1α by factor inhibiting HIF (FIH-1),
which blocks the association of HIF-1α with transcriptional co-activators CBP/
p300 and thus inhibits its transcriptional activity [20].
3. HIF-1α can be acetylated on lysine residue 532 in the ODDD domain. Acetylation
may affect HIF-1α hydroxylation and ubiquitination [21]. K532 acetylation by the
ARrest-Defective-1 (ARD-1) enhances the interaction between HIF-1α and pVHL
and, thus, leads to increased ubiquitination and concomitant proteasomal
degradation [21]. Mutation of lysine 532 to arginine has been reported to result in
increased stability of overexpressed HIF-1α [22]. Artificial maintenance of the
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acetylated state of HIF-1α by deacetylase inhibitor can lead to increased
degradation of HIF-1α [22]. All evidence indicates that acetylation of HIF-1α is a
signal for destabilization.
4. Direct phosphorylation on threonine 796 by mitogen-activated protein kinase
(MAPK) has recently been identified as a novel modification on HIF-1α and is able
to increase HIF-1 activity [23]. One mechanism to explain the increased
transcriptional activity is that HIF-1β binds preferentially to the phosphorylated
form of HIF-1α [24]. Moreover, it has been reported that phosphorylation at T796
in HIF-1α increases the affinity of the interaction between HIF-1α and the
transcriptional co-activator CBP/p300 [25]. Consistent with this, it is found that
phosphorylation of T796 prevents the hydroxylation of N803 by FIH [25]. More
recently, it is suggested that direct phosphorylation of HIF-1α by MAPK is not
correlated with its transcriptional activity, but that phosphorylation of the HIF-1α
co-activator p300 by MAPK increases the interaction between the HIF-1α C-TAD
and p300 [22]. Furthermore, HIF-1α S641 and S643 have been identified by mass
spectroscopy with in vitro phosphorylated recombinant HIF-1α to be MAPK targets
[26]. Inhibition of these phosphorylation sites has been shown to impair both
transcriptional activity and the nuclear localization of HIF-1α [26]. In addition,
phosphorylation of HIF-1α by glycogen synthase kinase (GSK)-3β may target
HIF-1α for proteasomal degradation [26].
5. HIF-1α can be oxidized. Hydroxyl radical and hydrogen peroxide can destabilize
HIF-1α protein in both normoxic and hypoxic conditions [27–28]. The oxidized
HIF-1α protein might be recognized and degraded by the ubiquitin-independent
20S proteasomal pathway, which primarily degrades cellular oxidized proteins
under oxidative stress conditions [29]. Therefore, in addition to the 26S
proteasomal pathway, 20S proteasomal pathway may play an important role in the
degradation of HIF-1α in ischemic conditions [1]. Moreover, studies have revealed
that S-nitrosation stabilizes HIF-1α protein and S-nitrosation of cysteine 800 of
HIF-1α promotes its interaction with CBP/p300, thus enhancing HIF-1α activation
[30]. However, a fluorescein polarization-based binding assay has demonstrated
that S-nitrosation of HIF-1α inhibits its p300 binding, which is contrary to a
previous report [31].
6. Sumoylation of HIF-1α has been reported to regulate its protein level and
transcriptional activity. Increasing the activity of RWD-containing sumoylation
enhancer (RSUME) could promote the sumoylation of HIF-1α by Ubc9 SUMO
conjugase and stabilize HIF-1α during hypoxia [32]. However, desumoylation by
SUMO-Specific Protease 1 (SENP-1) has been shown to be essential for the
stabilization of HIF-1α [33]. Sumoylation has also been found to work with
ubiquitination to reduce HIF-1 protein level and transcriptional activity [33–34].
In summary, HIF-1α protein level and transcriptional activity are highly regulated through
residue modifications such as hydroxylation, acetylation, phosphorylation, oxidation, and
sumoylation.
3. HIF-1 and amyotrophic lateral sclerosis (ALS)
Lou Gehrig’s disease, or ALS, affects approximately 2 in 100,000 people in the world. The
characteristics of ALS are damaged upper and lower motor neurons, causing weakness,
muscle atrophy, fasciculations, spasticity, hypo- or hyper-reflexia, and extensor plantar
responses [35]. Hypoxia, or an impaired oxygen supply, is a possible contributor to motor
neuron death. In occupations typically leading to intermittent and topical suppression of
blood flow around motor neuron axon at tissue levels, there is a two-fold increase in ALS
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risk [36]. In addition to occupation-induced hypoxia, chronically-reduced vascular perfusion
by aging or other factors can produce either chronic or episodic deficits in glucose
(hypoglycemia) and oxygen (hypoxia) [37]. This lack of glucose and oxygen fails to meet
the energy requirement of motor neurons, which will in turn induce neuronal death and lead
to the occurrence of ALS. Indeed, results from animal experiments have shown that in a
ALS animal model, SOD1G93A mutant mice, hypoxia is the major cause of motor neuron
death [38].
It is well known that one of the primary cellular responses to hypoxia is activation of the
HIF-1-vascular endothelial growth factor (VEGF) pathway. VEGF can induce angiogenesis
and increase blood supply to motor neurons during hypoxia through action on endothelial
cells [39]. This would be beneficial in ALS. However, it is implied that this pathway is
impaired in people with higher risk to ALS and in ALS patients. There is a negative
correlation between the VEGF level and the severity of hypoxemia in patients with ALS,
which suggests a deregulation of VEGF in ALS [40–41]. It has been shown that motor
neurons are prone to death in subjects with genetically impaired response to hypoxia [36].
ALS-like symptoms and neuropathology can be produced in mice by a targeted deletion of
the hypoxia response element that eliminates the expression of VEGF in response to hypoxia
[42]. This indicates that an impaired HIF-1-VEGF pathway may contribute to the
pathogenesis of ALS. Furthermore, overexpression of VEGF in SOD1G93A mutant mice
delays the degeneration of motor neurons and neuronal death and prolongs the survival of
these ALS mice [43].
The mechanism for the protective effect of VEGF in ALS possibly comprises two pathways:
its angiogenetic effect and its direct action on motor neurons. VEGF acts on vascular
endothelial cells to induce the proliferation and migration of endothelial cells and to form
new micro-vessels [39]. The newly formed micro-vessels can increase the blood supply to
motor neurons in brain and spinal cords [39]. By this mechanism, VEGF can prevent the
death of motor neurons and postpone the occurrence of ALS. Also, VEGF acts directly on
motor neurons as neurotrophic or neuroprotective factors [44]. VEGF supports the survival
of primary motor neurons and a motor-like cell line in vitro and could protect these motor
neurons from hypoxia-induced cell death by binding with neuropilin-1, a receptor known to
be involved in axon guidance during development [42, 45]. Through these direct actions,
VEGF can increase motor neurotrophy and activate the growth of motor neuron axon during
the pathogenesis of ALS, thereby postponing the progression of ALS.
Besides VEGF, erythropoietin (EPO) may also mediate the protective effect of HIF-1. It has
been reported that EPO levels are significantly decreased in cerebrospinal fluids from
patients with differing severity and duration of ALS [46], while EPO immunoreacitivity is
significantly increased in midbrain, brain stem, and cortex of the SOD1G93A mutant mice
[47]. In this SOD1G93A mutant mouse ALS model, administration of EPO suppresses the
onset and progression of ALS by preventing motor neuron death and inflammation [48–49].
These EPO neuroprotective effects indicate that EPO administration may be a new
therapeutic approach to ALS.
Since increasing VEGF and EPO expression are both beneficial for the survival of motor
neurons, their transcriptional regulator, HIF-1, may also serve as a potent therapeutic
strategy for ALS. Indeed, the iron chelator M30, which up-regulates HIF-1 expression,
protects NSC-34 motor neuron cells from oxidative damage in vitro and significantly delays
the onset of ALS in SOD1G93A mutant mice [50] (Table 2).
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4. HIF-1 and Alzheimer’s disease (AD)
The incidence of Alzheimer’s disease is 15% among those 65 years and older, and is close to
50% for those aged over 85 years [51]. Patients with AD display loss of synapses and
neurons, as well as extra-cellular senile plaques and intracellular neurofibrillary tangles
(NFTs) [52]. Senile plaques consist largely of aggregated amyloid-β peptide (Aβ), which is
liberated from the holoprotein, amyloid precursor protein (APP), by sequential cleavages
mediated by the β-secretase β-site APP cleavage enzyme 1 (BACE1) and the γ-secretase
complex [53]. NFTs are made up a highly phosphorylated form of the microtubule-
associated protein tau [54]. Both Aβ accumulation and NFTs are pathological hallmarks of
Alzheimer’s disease which are responsible for induction of oxidative stress,
neuroinflammation, and calcium deregulation [55–56].
Results from both basic research and clinical trials have confirmed that HIF-1 activation
may be a potent strategy to postpone the pathogenesis and ameliorate the outcomes of AD.
The HIF-1 inducer, M30, has been reported to increase the HIF-1α protein level and elevate
expression of the HIF-1 target genes, VEGF and EPO. It has been reported that M30
simultaneously attenuates tau phosphorylation and protects cortical neurons against Aβ (25–
35) toxicity [57]. Overexpression of HIF-1α has been shown to protect the rat sympathetic
nerves-like cell line PC12, the central nervous system cell line B12, and primary cultured
cortical neurons from Aβ-induced neurotoxicity [58], possibly through activating glycolytic
and hexose monophosphate shunt-related enzymes. Clinical applications of HIF-1 inducers
have also demonstrated the neuroprotective effect of HIF-1 in AD (Table 2). Deferoxamine
(DFO), a widely used HIF-1 inducer, has been used in clinical trial in AD patients and
slowed cognitive decline [59]. These studies suggest that increasing HIF-1 activity can
prevent neuron death and ameliorate these symptoms of AD.
The mechanism responsible for neuroprotective effects of HIF-1 in AD pathogenesis may
rely on its regulation of various physiological processes. HIF-1 activation promotes cellular
response to low oxygen, reduced glucose supply, and oxidative stress. As a result, it
contributes to cell survival [3]. It is known that reduced cerebral blood flow [60], impaired
glucose uptake and metabolism [61], and increased oxidative stress [62] are involved in the
pathogenesis of AD. HIF-1 may mitigate the deleterious effects by the factors discussed
below.
1. It has been shown that individuals who have suffered severe hypoxia or ischemia
are more susceptible to developing AD [63]. Reduced blood oxygenation has been
found in people with higher AD risk [64]. Cerebral blood flow reduction is present
in the early stages of AD pathogenesis [60]. In vitro results have also shown that
primary cortical neurons treated with Aβ and hypoxia exposure exhibit a higher cell
death than treatment with Aβ alone [65]. In brains of transgenicAD mice, hypoxia
elevates the β-cleavage of amyloid-β precursor protein and increases the expression
of γ-secretase, which in turn increases Aβ generation and senile plaque formation
[66]. HIF-1 can induce the erythropoiesis and angiogenesis to increase oxygen
delivery and supply [3]. Thus, an increase of HIF-1 activity might reduce the risk
of AD by suppressing the Aβ generation and AD occurrence induced by hypoxia.
2. Accumulating data have shown that impaired glucose uptake and metabolism may
increase the risk of AD [61]. The reduced glucose uptake is due to decreased
expressions of neuronal glucose transporters (GLUT-1 and GLUT-3) [67]. Since
GLUT-1 and GLUT-3 are target genes of HIF-1, induction of HIF-1α expression
may restore the glucose uptake and postpone the progression of AD.
3. Both Aβ-accumulation and NFTs induce oxidative stress in neurons, which in turn
cause severe neuronal death [62]. HIF-1 may prevent neuronal death in the AD
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brain through elevating glycolysis and the hexose monophosphate shunt and
increasing the reducing ability of neurons [4, 58].
4. HIF-1 target gene EPO may also mediate its neuroprotective effects. Erythropoietin
is found to be secreted by neurons and to act on neurons directly through its
receptor [68–69]. It has been shown that EPO is able to block the Aβ-generated
neuronal apoptosis and that this protection is completely abolished by co-treatment
with an anti-EPO neutralizing antibody [70]. In animal studies, EPO has been
found to reduce the cognitive and behavioral symptoms of mechanical brain injury
[71]. Recently, EPO has come into consideration as a possible treatment for AD.
Through regulating target genes expression, HIF-1 may prevent AD occurrence, postpone
AD progression, and ameliorate AD symptoms. However, many important questions remain
unanswered. First, it is still unclear whether the suppression of HIF-1 activity can induce
AD, although the impairment of its down-streamed pathways has been widely found to
contribute to the occurrence of AD, AD progression, and neuron death in patients. Second,
besides causing oxidative stress, Aβ and NFTs also induce caspases and other neuronal
apoptosis-related pathways [72]. Whether HIF-1 interacts with these pathways during AD
pathogenesis is unclear. Third, most of the present available results are from models with
activated HIF-1. Results from HIF-1α knock-out models are needed to identify whether
HIF-1 is essential for the protective effects of Aβ preconditioning or iron chelators.
Moreover, it is known that inflammatory responses mediated by micro-glia contribute to the
progression of AD [73]. Since HIF-1 can modulate the inflammatory response of
macrophages in the blood [74], further research on HIF-1’s functions in the inflammatory
processes of glial cells in AD pathogenesis will be helpful for understanding the applications
of HIF-1 in clinical trials of AD.
5. HIF-1 and Parkinson’s disease (PD)
Parkinson’s disease (PD) affects 1.5–2% in the population over 60 years of age [75]. It
mainly results from a progressive loss of dopaminergic neurons in the substantia nigra,
causing classical motor symptoms of bradykinesia, rigidity and resting tremors [76]. Thus,
we may expect that restoration of dopamine (DA) synthesis and secretion levels may help to
ameliorate the PD patients’ symptoms. Furthermore, it is suggested that mitochondrial
dysfunction and the associated oxidative stress is the main mechanism responsible for
neurodegeneration in PD [77]. DAergic neurons are particularly prone to oxidative damage
due to high levels of inherent reactive oxygen species that are produced during DA synthesis
or its breakdown by monoamine oxidases [78–79].
Parkinson’s disease can be induced in primates and mice by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), which is converted into an active toxin 1-methyl-4-
phenylpyridinium (MPP+) in astrocytes. Accumulation of MPP+ is able to inhibit oxidative
phosphorylation via inhibition of complex I in mitochondrial electron transport chain,
resulting in energy failure and nigrostrital neuron death. It is reported that MPTP treatment
inhibits HIF-1α accumulation in dopaminergic cell lines PC12 and in mice [80], suggesting
that HIF-1 activity is impaired in PD. The most direct linkage between HIF-1 and PD is the
tyrosine hydroxylase (TH), which is the rate-limiting enzyme in the synthesis of DA in
DAergic neurons [81]. Promoter activity studies suggest that the TH gene is under the
control of a hypoxia response element [82–83]. Hypoxia and DFO, both are known to
upregulate HIF-1, can increase TH expression in rat brains [84–85]. Meanwhile, a
conditional knock-down of HIF-1α in mice results in a 40% decrease of TH expression in
substantia nigra [86]. Injection of the PHD inhibitor FG0041 increases HIF-1 activity and
the extracellular DA level in the striatum of the rat brain [87]. Furthermore, administration
of HIF-1 activator cobalt chloride raises the DA release [87]. Beside the increased DA
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synthesis, the secretion of DA is also increased through K+-depolarization in the FG0041
and cobalt chloride-treated rats [87]. Therefore, through increasing synthesis and secretion
of DA, HIF-1 may prevent the PD pathological process.
Recent studies have also demonstrated that HIF-1 may protect DAergic neurons through
alteration in iron homeostasis and defense against oxidative stress and mitochondrial
dysfunction. The 2-oxoglutarate analogue 3,4-dihydroxybenzoate (DHB) effectively inhibits
PHDs activities. It has been found that 3,4-DHB treatment is able to stabilize HIF-1α
protein, leading to the elevation of HIF-1 target genes expression, such as ferroportin and
heme oxygenase (HO)-1, in the substantia nigra. Both ferroportin and HO-1 are involved in
an attenuation of iron accumulation as a result of MPTP administration [88]. The research
group also reported that the iron chelator clioquinol increases HIF-1α within DAergic
neurons and protects against MPTP-induced nigral cell death [88]. Moreover, DFO is shown
to prevent neurotoxicity in the MPTP-mouse model of PD [89]. In addition, Ben-Shachar et
al. have demonstrated that intracerebroventricular-injection of DFO protects the rat brain
from DAergic neurodegeneration induced by 6-hydroxydopamine [90].
HIF-1 target genes EPO and VEGF have been shown to contribute to the protection of
neurons from PD pathogenesis. EPO is neuroprotective against the DAergic neurotoxin, 6-
hydroxydopamine, in both the DAergic cell line MN9D and primary DAergic neurons [91].
In an embryonic rat explant model, DAergic neurons, particularly, exhibit increased survival
in response to VEGF application [92], suggesting that VEGF may promote the growth of
DAergic neurons. Primary midbrain neural precursor cells from mice with conditional
inactivated HIF-1 in substantia nigra show a reduced differentiation to DAergic neurons,
whereas VEGF partially recovers DAergic proliferation and differentiation in these cells
[86]. In addition, a mouse model of pan-neuronal overexpression of VEGF demonstrates
that VEGF provides protection against MPTP toxicity in nigral cells [88]. In conclusion,
many reports have revealed that HIF-1 can increase dopamine synthesis and DAergic neuron
growth. All the experimental evidence supports the concept that HIF-1 may have a
neuroprotective effect in PD brain.
6. HIF-1 and Huntington’s disease (HD)
Huntington’s disease (HD) results from genetically programmed degeneration of neurons,
specifically in the basal ganglia at the base of the brain [93]. Mutated huntingtin protein
seems responsible for the neuronal death in HD [94]. Mutant huntingtin protein leads to
transcriptional repression of many genes, including those that control mitochondrial energy
metabolism such as peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α)
[95]. The impaired mitochondrial biogenesis, induced by suppression of PGC-1α, plays an
important role in HD pathogenesis. Indeed, deletion of PGC-1α leads to similar striatal
degeneration and behavioral abnormalities in animal models of HD. By contrast, restored
mitochondrial proliferation and biogenesis by overexpression PGC-1α prevents the striatal
degeneration induced by transgenic- expressed mutant huntingtin protein [96]. In addition to
its deleterious effects in neurons, huntingtin protein in glial cells also induces HD
pathogenesis through mitochondria dysfunction [97]. One of the most important
neuroprotective effects of astroglial cells is the uptake of glutamate, which prevents neurons
from excitotoxicity induced by glutamate [98]. Huntingtin protein is able to induce
mitochondrial dysfunction and suppress glutamate uptake in primary astrocytes, which
reduces the neuroprotective ability of astrocytes [99]. Using the transgenic mouse model of
HD brain (R6/2 mice), Lieven et al. have reported that expression of astroglial glutamate
transporter-1 is lower and the glutamate uptake ability is suppressed [100]. In this way,
huntingtin protein-induced mitochondrial metabolism dysfunction in the brain serves as the
primary cause of HD pathogenesis.
Zhang et al. Page 7













The research on huntingtin protein-induced mitochondrial dysfunction raises the hypothesis
that an alternate strategy for compensating for mitochondrial energy deficits may prevent
mutant huntingtin protein-induced neuronal death. HIF-1 regulates glycolysis and hexose
monophosphate shunt, which increases the production of adenosine triphosphate (ATP) and
nicotinamide adenine dinucleotide phosphate (NADPH) for cell survival. Although in
glycolysis and in the hexose monophosphate shunt, cells need more glucose to produce ATP
to meet their energy requirements, these two metabolism pathways can make up for the
energy shortage induced by a mitochondrial biogenesis defect. Therefore, increasing HIF-1
activity may prevent neurons from mutant huntingtin protein damage.
Many strategies for HIF-1 activation have been used to prevent HD pathogenesis. The
mitochondrial toxin 3-nitropropionic acid is widely used to induce mitochondrial
dysfunction and HD in animal models. Three HIF-1 inducers, CoCl2, mimosine, and DFO,
have been reported to significantly attenuate cytotoxicity induced by 3-nitropropionic acid in
glioma cells. Another metal chelator, clioquinol, increases HIF-1α expression and reduces
cell death and mutant protein accumulation in both a tissue culture model and a transgenic
Huntington’s animal model [101–102]. Several plausible mechanisms that may mediate
HIF-1’s protective effects have been proposed. HIF-1 activation induces the expression of
glucose transporters as well as glycolytic enzymes. The enhanced glucose transport coupled
with glycolytic pathways may compensate for the reduced ATP supply from compromised
mitochondria. Moreover, the end product of glycolytic pathways is pyruvate and it is an
antioxidant capable of scavenging radicals [103]. Therefore, HIF-1 induction may provide
cytoprotection by increasing energy supply and contributing to cellular redox homeostasis.
In addition, it has been shown that the protective effect of HIF-1 is not PGC-1α dependent,
suggesting that HIF-1 may ameliorate the damage through its own target genes [104]. This
indicates that HIF-1 may prevent neuronal death under conditions of HD and therefore
increasing HIF-1 activity may be a strategy for prevention or therapy of HD.
7. Recent drug development based on HIF-1 induction in
neurodegenerative diseases
HIF-1 hydroxylases include prolyl hydroxylases (PHDs) and asparaginyl hydroxylase (FIH).
PHDs can induce HIF-1α degradation while FIH inhibits HIF-1 activity. Inhibiting the
hydroxylases has been shown to provide protective effects in neurodegenerative diseases.
The following discusses the recent findings on the hydroxylase inhibitors and related drug
development progress.
The ferrous ion bound at the active sites is essential for the activity of PHDs [105]. Cobalt
displaces the single free ferrous at the active site and thus deactivates the hydroxylases [11].
Therefore, cobalt is able to stabilize HIF-1α. It has been reported that cobalt treatment can
increase DA release in rats [87]. Moreover, the preconditioning of rat C6 astroglia cells with
the CoCl2 provides extensive cytoprotective effects against metabolic insults induced by
mitochondrial toxin 3-nitropropionic acid [102].
Iron chelators have been traditionally regarded to provide neuroprotection by sequestering
redox-active iron and thereby prevent hydroxyl radical formation [106]. More and more
evidence demonstrates that iron chelators’ neuroprotection may result, at least partly, from
inhibiting the activation of PHDs [106]. The hexadentate siderophore DFO (Fig. 1.1)
possesses a high and specific affinity for iron [107]. The sequestering of ferrous ion by DFO
prevents formation of a catalytically active center in the PHDs and induces HIF-1 activation
[11]. DFO has been demonstrated to confer neuroprotection by inducing HIF-1 expression in
a variety of animal ischemia models [19]. Intracereventricular injection of DFO protects
against dopaminergic neurodegeneration induced by 6-hydroxydopamine [90] and prevents
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MPTP induced neurotoxicity in mouse models of PD [89]. Compromised mitochondrial
function in neurons and glial cells has been observed in HD and AD. Preconditioning of C6
astroglial cells with DFO can activate HIF-1 and thereby attenuate cytotoxicity induced by
mitochondrial inhibitor 3-nitropropionic acid [102].
Another example of iron chelators is clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) (Fig.
1.2). Clioquinol is a lipophilic bioavailable metal chelator and has been investigated for the
treatment of neurodegenerative diseases [106]. Clioquinol-treated transgenic HD mice
(R6/2) demonstrate improved behavioral and pathologic phenotypes, including decreased
huntingtin aggregate accumulation as well as enhanced motor functions and survival [101].
It is also reported that clioquinol protects against MPTP-induced nigral dopaminergic cell
loss and up-regulates HIF-1α within these neurons [88], indicating that it may provide
neuroprotection in PD.
Furthermore, novel compounds compromising aromatic heterocyclic related to pyridine
derivatives, such as 8-hydroxyquinolines, are developed as selective PHDs inhibitors [19].
Hydroxyquinolines can exert their physiological properties through bidentate chelation of
metal ions [19]. Among a series of novel multifunctional iron chelators derived from 8-
hydroxyquinolines, the compound M30 (Fig. 1.3) is found to be the most potent, nontoxic,
lipophilic, and BBB-permeable selective iron chelator [106]. M30 and another iron chelator
HLA20 (Fig. 1.4) are both designed from the brain-permeable iron chelator VK28 (Fig. 1.5)
and chemically attached to the neuroprotective N-propargyl moiety of the anti-Parkinson
drug rasageline. As a result, both M30 and HLA20 inherit some of the neuroprotective
properties from VK28 and rasageline [106]. M30 is able to activate the HIF-1 signaling
pathway and increase the transcription of HIF-1-dependent genes, including VEGF, EPO,
enolase-1, p21, and TH, in rat primary cortical cells [57]. Both M30 and HLA20 enhance
HIF-1α mRNA and protein expression as well as its nuclear translocation in motor-neuron-
like cell line, NSC-34 cells [50]. Furthermore, both M30 and HLA20 increase the levels of
the endogenous HIF-1-dependent genes, including enolase-1, VEGF, and brain derived
neurotrophic factor (BDNF) in NSC-34 cells [50]. In addition, treatment with M30 provides
benefits in G93A-SOD1-mutant ALS transgenic mice, increasing their survival and delaying
the onset of neurological dysfunction [50].
Since both PHDs and FIH are members of the Fe(II)- and 2-oxoglutarate-dependent
oxygenase superfamily, besides cobalt and iron chelators, analogues of 2-oxoglutarate can
also inhibit hydroxylation and induce HIF-1α protein [11]. Analogues of 2-oxoglutarate are
more selective for PHDs and FIH than simple iron chelators [11]. Two examples of 2-
oxoglutarate analogues are 3,4-DHB (Fig. 1.6) and FG0041 (Fig. 1.7). It has been reported
that 3,4-DHB is significantly more selective in inhibiting FIH than PHDs [105]. It protects
against MPTP-induced neurotoxicity both in vitro and in vivo [19]. In addition, 3,4-DHB
also elevates the expression of HIF-dependent genes such as heme oxygenase-1 and
manganese superoxide dismutase in the presence of MPTP [88]. FG0041 increases HIF-1
activity and the extracellular DA level in the striatum of the rat brain [87]. Both 3,4-DHB
and FG0041 may prevent the PD pathological process by inducing HIF-1 activation.
In summary, both iron chelators and 2-oxoglutarate analogues have demonstrated
neuroprotective effects and they may become potential treatments against neurodegenerative
diseases. Iron chelators may also exert their neuroprotective effects through other
mechanisms besides inhibiting PHDs and inducing HIF-1 signaling pathway. Therefore,
understanding the exact mechanisms responsible for iron chelators’ protective effects will
help the development of new therapeutic strategies in treating neurodegenerative diseases.
Furthermore, since PHD inhibitors display different potencies to the three PHD subtypes
[108], it may be possible to develop PHD inhibitors with different subtype selectivity which
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exhibit different biological properties. Another issue to consider when developing PHD
inhibitors for neurodegenerative diseases is the cellular concentration of 2-oxoglutarate in
the brain tissue of interest. Study has shown that 2-oxoglutarate may decrease the cellular
potency of a competitive PHD inhibitor [108]. Thus, to specifically inhibit the intracellular
PHDs, a competitive inhibitor with a low Ki should be developed.
Conclusions
HIF-1’s protein level and transcriptional activity are largely regulated by post-translational
modifications on different amino acid residues of the α subunit. Many lines of evidence have
demonstrated that HIF-1 is involved in the pathogenesis of AD, PD, ALS, and HD.
Extensive experimental studies have revealed that activating HIF-1 by inhibiting the
activation of PHDs can provide neuroprotection, ameliorate the outcomes, or prevent the
pathogenesis in these pathological conditions. The beneficial effects of HIF-1 arise mainly
from the increased expression of HIF-1 target genes, which combat oxidative stress,
improve blood oxygen and glucose supply, promote glucose metabolism, regulate iron
homeostasis, activate the synthesis of dopamine, and block cell death signal pathways.
Increasing HIF-1 activity may be an important potential strategy for preventing the onset or
ameliorating the pathogenesis of these diseases. The applications of HIF-1 inducers in
neurodegenerative models have shown positive effects in many cases and are worth
pursuing further.
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Chemical structures of HIF hydroxylase inhibitors.
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Domain structure and major modification sites of HIF-1α.
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Summary of neuroprotective effects of HIF hydroxylase inhibitors associated with HIF-1
activity.
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Table 1
Summary of HIF-1α protein modifications.
Modifications Enzymes or Oxidants Involved Target Amino Acids Outcomes Reference
Prolyl hydroxylation Prolyl hydroxylase domains
(PHDs)
P402 and 564 Recognition signal for binding of
pVHL E3 ligase
[109]
Polyubiquitination pVHL E3 ligase K Signal for Degradation [18]
[110]
Acetylation Arrest-defective-1 (ARD1) K532 ↑Interaction of HIF-1α with pVHL
E3 ligase
[21]
Asparagine hydroxylation Factor inhibiting HIF-1 (FIH-1) N803 ↓Interaction of HIF-1α with CBP/
p300
[111]
Phosphorylation MAPK T796 ↑Transcriptional activity [23]
S641 and 643 ↑Transcriptional activity and
nuclear localization
[26]
S551, T555 and S589 Target for degradation [26]
Oxidation Hydroxyl radical C800 HIF-1α degradation [28]
H2O2 HIF-1α degradation [27]
Sumoylation E3 SUMO ligase Within ODD ↓Transcriptional activity [34]




enhancer (RSUME) and SUMO
conjugase Ubc9
HIF-1α stabilization [32]
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Table 2
Summary of HIF-1 inducers and their mechanisms responsible for HIF-1’s neuroprotection in
neurodegenerative diseases.




ALS M30 Novel iron chelator; sequestering of ferrous iron,
preventing formation of a catalytically active centre






AD DFO Iron chelators; sequestering of ferrous iron,
preventing formation of a catalytically active centre









PD Cobalt Displacing the free ferrous at the active site of
hydroxylases thereby inhibiting HIF-1
hydroxylation





DFO Iron chelator; sequestering of ferrous iron,
preventing formation of a catalytically active centre
in the HIF hydroxylases thereby inducing HIF-1
activation
FG0041 3,4-DHB Analogues of 2-oxoglutarate; bind to the active site
of HIF hydroxylase, inhibiting HIF hydroxylase
HD Cobalt Displacing the free ferrous at the active site of
hydroxylases thereby inhibiting HIF-1
hydroxylation
↑Production of ATP and
NADPH
↑Glia cells activity
DFO Clioquinol M30 Iron chelators; sequestering of ferrous iron,
preventing formation of a catalytically active centre
in the HIF hydroxylases thereby inducing HIF-1
activation
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